

Disclosure of Relevant Financial or Non-financial/Strategic Business Relationships or Partnerships

'The Online Experience'

The American Society of Breast Surgeons 25th Annual Meeting General Session

Friday, April 12 – Sunday, April 14, 2024

Orlando, FL

The Society is charged with ensuring its CME activities are balanced, independent, objective, and scientifically rigorous, through, but not limited to, by identifying and mitigating relevant financial relationships or non-financial/strategic business relationships or partnerships (relationships) between individuals in control of educational content and ineligible companies. By identifying and mitigating relevant relationships, we work together to create a protected space to learn, teach, and engage in scientific discourse free from influence from individuals that may have an incentive to insert commercial bias into a CME activity.

As a CME provider accredited by the [Accreditation Council for Continuing Medical Education \(ACCME\)](#), the ASBrS requires individuals in control of the educational content of a CME activity (including but not limited to, authors, content reviewers, editors, education-based committees, and ASBrS staff) to disclose all financial and non-financial/strategic business relationships or partnerships (relationships) with ACCME-defined ineligible company, within the 24 months prior to their involvement with the CME activity. An ineligible company is a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Please review the following examples at <https://accme.org/rule/eligibility/>.

Individuals in control of educational content must review and adhere to the ASBrS CME Activity Policy and Disclosure Process as well as complete the applicable ASBrS Disclosure Form at the time they are invited to participate in a CME activity. Participation is not confirmed without the completion of the disclosure form and will be contingent upon mitigation, if necessary.

Owners or employees of ineligible companies are excluded from controlling content or participating as planners or faculty in a CME activity. The **owners** and **employees** of ineligible companies are considered to have unresolvable financial relationships and must be excluded from participating as planners or faculty and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.

There are three exceptions to this exclusion—employees of ineligible companies can participate as planners or faculty in these specific situations:

- a. When the content of the activity is not related to the business lines or products of their employer/company.
- b. When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research and they do not make care recommendations.

- c. When they are participating as technicians to teach the safe and proper use of medical devices, and do not recommend whether or when a device is used.

To assist all CME planners and contributors in identifying relevant relationships, ASBrS staff provides a sample list of typical relevant relationships and possible methods for mitigation –as well as examples of non-compliant actions. However, this list is not an exhaustive list of all scenarios. Participants are required to disclose all possible competing interests, both financial and non-financial, that could interfere with, or could reasonably be perceived as interfering with, their ability to provide objective and valuable contributions to the ASBrS CME activity.

All identified relevant relationships are mitigated prior to the education activity being delivered to learners per ACCME Standards. The inability to mitigate an identified relevant relationship results in the participant’s withdrawal from participation in the CME activity.

A list of disclosures from all CME planners and contributors, as well as all potential and actual mitigation methods (including any instances of non-compliance), are documented and maintained by ASBrS staff. This list is made available to all CME activity planners.

The non-compliance process is initiated when an individual’s (in a position to control educational content of the CME activity) *undisclosed* relationship(s) with an ineligible company is identified or reported during or after the CME activity. The Board of Directors, CME Committee, Ethics Committee, and applicable committee chair(s) will discuss the act of noncompliance and agree upon a resolution.

Oversight

The CME Committee and Ethics Committees ensure that there is no commercial bias or influence in ASBrS CME activities. They work together to ensure proper conflict management. Members of these committees serve as additional oversight, participating and observing ASBrS CME activities to look for any evidence of bias and ensure compliance with the ASBrS policies.

Reporting Conflicts

Participants of any ASBrS CME activity may report any improprieties on the applicable evaluation form and to the CME and Ethics Committee at cme@breastsurgeons.org.

Please note we have advised speakers it is their responsibility to also disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The following individuals and groups have been involved in the planning, mitigation, implementation, approval, evaluation, and/or oversight of this activity. All disclosed relationships are within the 24 months prior to their involvement with the CME activity. All relevant disclosed relationships have been mitigated by a designated CME Committee Official

Name of Individual	Individual's Role(s) in Activity (e.g. Planner, Reviewer, Speaker, Author, Moderator, Panelist)	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)	Mechanism(s) Implemented to Mitigate Relevant Financial Relationships Appropriate to Role(s) in the Activity
<i>J. Michael Dixon, Professor, OBE, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Deborah Farr, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Roshni Rao, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Lorraine Tafra, MD</i>	<i>Moderator</i>	<i>AL Gore; Breast Care Architects</i>	<i>Fee; Consultant (AL Gore) Fee for services; Founding Partner (Owner) (Breast Care Architects)</i>	<i>The Breast Care Architects (Owner) relationship meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.' Educational content will not be presented; the session faculty were selected by the annual meeting program chair to address broader implications and recommendations. The other financial relationship is not relevant the role.</i>
<i>Paul Baron, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Michele Carpenter, MD</i>	<i>Speaker</i>	<i>Perimeter Medical</i>	<i>Training and Honorarium; Advisory and education</i>	<i>The financial relationship is relevant to the role. Peer review of presentation content was performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</i>
<i>Anshumi Desai, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Massimo Ferrucci, MD, PhD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Nicketti Handy, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Katrina Mitchell, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Courtney Vito, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Michael Alvarado, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Patrick Borgen, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Mahmoud El-Tamer, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Carla Fisher, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<p><i>Katherine Kopkash, MD</i></p>	<p><i>Speaker</i></p>	<p><i>SimBioSys; Exact Sciences; Vector Surgical</i></p>	<p><i>Honorarium; Consultant - Relationship Ended) (SimBioSys); Honorarium; Advisory Board - Relationship Ended (Vector Surgical); Honorarium; Consultant - Relationship Ended (Vector Surgical)</i></p>	<p><i>Financial relationship(s) are not relevant to the role.</i></p>
<p><i>Helen Pass, MD</i></p>	<p><i>Moderator</i></p>	<p><i>Exact Sciences; Endomag</i></p>	<p><i>Honorarium; speaker (Exact Sciences); Honorarium; speaker (Endomag)</i></p>	<p><i>Financial relationship(s) are not relevant to the role.</i></p>
<p><i>Shawna Willey, MD</i></p>	<p><i>Speaker</i></p>	<p><i>Videra Surgical; EndoMagnetics; Lumicell; Pacira Pharmaceuticals; Medtronic; Hologic; TransMed 7; TME/Aptitude; Myriad; Cairn Surgical</i></p>	<p><i>Honorarium; Speaker - Relationship Ended (Videra Surgical); Honorarium, Travel expenses; Speaker (Endomagnetics); Honorarium; Member, DSMB (Lumicell); Honorarium, Travel expenses, Speaker (Pacira Pharmaceuticals); Honorarium, Travel expenses; Speaker (Medtronic); Honorarium, Travel expenses; Speaker, consultant (Hologic); Nothing; Scientific Adviser (Ownership Interest) (TransMed7); Honorarium, Travel expenses; Consultant (TME/Aptitude); Honorarium; Focus Group Member - Relationship Ended (Myriad); Food & Beverage, Scientific Advisory Board (Cairn Surgical)</i></p>	<p><i>The TransMed 7 (ownership interest) relationship is not relevant to the role. Dr. Willey meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.' TransMed7 products and business lines are not related to the presentation topic about RVUs. Peer review of presentation content was performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material. The other financial relationships are not relevant to the role.</i></p>

<i>Katharine Yao, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Akiko Chiba, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Beth DuPree, MD</i>	<i>Speaker</i>	<i>Medtronic; Perimeter Medical; Prelude Dx; InnerStill Health; Signal Relief; Gateway Sciences</i>	<i>Honorarium; Speaker (Medtronic); Honorarium, Stock options; Consultant, independent contractor (Perimeter Medical); Honorarium; Speaker (Prelude Dx); Equity, Medical Director (Ownership Interest) (Innerstill Health); Honorarium; Medical director (Signal Relief); Nothing; Medical Director (Gateway Sciences)</i>	<i>Dr. DuPree's relationships with InnerStill Health, Signal Relief, and Gateway Sciences (ownership interest; Medical Director) meets ACCME exceptions 'a. When the content of the activity is not related to the business lines or products of their employer/company.' The other financial relationships are not relevant to the role. Peer review of presentation content was also performed by the CME committee. The presentation was about social media use and not related to her various relationships. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</i>
<i>Lillian Erdahl, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Camelia Lawrence, MD</i>	<i>Speaker</i>	<i>Hologic; Myriad Genetic</i>	<i>Honorarium; Consultant (Hologic); Honorarium, Advisor (Myriad Genetic)</i>	<i>Financial relationships are not relevant to the role.</i>
<i>Stephanie Serres, MD, PhD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jennifer Tseng, MD</i>	<i>Moderator</i>	<i>Intuitive Surgical; Elucent</i>	<i>Research Funding; Site PI for Clinical Trial - Relationship Ended (Intuitive Surgical); Travel Expenses, Training Course - Relationship Ended (Elucent)</i>	<i>Financial relationships are not relevant to the role.</i>
<i>Zahraa Al-Hilli, MD, MBA</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jane Mendez, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Lisa Newman, MD, MPH</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kristin Rojas, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Preya Ananthkrishnan, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Marissa Howard-McNatt, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Henry Kuerer, MD, PhD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>William Sikov, MD</i>	<i>Speaker</i>	<i>Lilly Oncology; Seagen; DaiichiSankyo</i>	<i>Honoraria, speaker's training for promotional presentations - Relationship Ended (Lilly Oncology); Honoraria, speaker's training for promotional presentations - Relationship Ended (Seagen); Honoraria, speaker's training for promotional presentations - Relationship Ended (DaiichiSankyo)</i>	<i>All financial relationships are relevant. Educational content has been peer reviewed the CME committee; clinical recommendations are free of commercial bias and the content of the presentation does not actively promote commercial material.</i>
<i>Bret Taback, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Julia White, MD, FACR, FASTRO</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>David Gruen, MD, MBA, FACR</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Carinne Anderson, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Sarah Blair, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kristalyn Gallagher, DO, FACOS, FACS</i>	<i>Moderator</i>	<i>Endomag/Mammotome</i>	<i>Honorarium; Peer to peer conversation</i>	<i>The financial relationship is not relevant to role.</i>

<i>Manpreet Kohli, MD</i>	<i>Moderator</i>	<i>Impedimed</i>	<i>Honorarium; Oncology Advisory Board Committee Member</i>	<i>The financial relationship is not relevant to role.</i>
<i>Ekaterini Tsiapali, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Nora Hansen, MD</i>	<i>Moderator</i>	<i>Merck</i>	<i>Honorarium; Speaker's forum</i>	<i>The financial relationship is not relevant to role.</i>
<i>Kelly Hunt, MD</i>	<i>Speaker</i>	<i>Armada Health; AstraZeneca; Cairn Surgical; Eli Lilly & Co.; Lumicell</i>	<i>Stipend; Medical Advisory Board (Armada Health); Stipend, Medical Advisory Board (AstraZeneca); Funding to institution, Researcher (Cairn Surgical); Research funding to institution, Researcher - Relationship Ended (Eli Lilly & Co.); Research funding to institution, Researcher (Lumicell)</i>	<i>Financial relationships are not relevant to role.</i>
<i>E. Shelley Hwang, MD, MPH</i>	<i>Speaker</i>	<i>Exai bio; Lumicell; Clinetic</i>	<i>Stock options, Advisory board (Exai bio); Travel, Advisory board (Lumicell); Steering committee (Clinetic)</i>	<i>Dr. Hwang's financial relationship with Exai Bio (stock ownership) meets ACCME exception: 'a. When the content of the activity is not related to the business lines or products of their employer/company.' Educational content has been peer reviewed the CME committee. The presentation is summarizing data from presentations from another meeting and is free of commercial bias and does not actively promote commercial material. The other relationships are not relevant to her role.</i>

<i>Cory Donovan, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jay Harness, MD</i>	<i>Moderator</i>	<i>Medtronic Enabling Technology; Lumicell</i>	<i>Honorarium, Speaker - Relationship Ended (Medtronic Enabling Technology); Honorarium, Chair- Data Safety Monitoring Board (Lumicell)</i>	<i>Financial relationships are not relevant to the role.</i>
<i>Jessica Maxwell, MD</i>	<i>Moderator</i>	<i>Dilon Technologies</i>	<i>Honorarium; Advisory Board</i>	<i>The financial relationship is not relevant to the role.</i>
<i>Taryn Smith, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Israel Falade</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kush Lohani</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Julie Margenthaler, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Tesia McKenzie, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Anna Stachura, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Tesia McKenzie, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Anna Stachura, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Preeti Subhedar, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Paul Thiruchelvam, MD, PhD, FRCS</i>	<i>Moderator</i>	<i>Stryker; Endomagnetics; Cytoveris</i>	<i>Honorarium; Speaker Fee (Stryker); Honorarium; Speaker Fee (Endomagnetics); Consultant, Fees (Cytoveris)</i>	<i>Financial relationships are not relevant to the role.</i>
<i>Danielle Thompson, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Elle Clelland</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Peter Fasching, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Andreas Giannakou, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Nimmi Kapoor, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Keva Li</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Mara Piltin, DO</i>	<i>Speaker</i>	<i>Intuitive Surgical</i>	<i>Research funding (institute -FDA IDE clinical trial for robotic mastectomy)</i>	<i>The financial relationship is not relevant to role.</i>

<i>Julia Tchou, MD, PhD</i>	<i>Moderator</i>	<i>BD</i>	<i>Consultation fees; Consultant</i>	<i>The financial relationship is not relevant to role.</i>
<i>Mediget Teshome, MD</i>	<i>Moderator</i>	<i>Endomagnetics, LTD</i>	<i>Travel, accommodations, food; Conference Support - Relationship Ended</i>	<i>Financial relationship is not relevant to role.</i>
<i>Vivian Bea, MD, MBS, FACS</i>	<i>Speaker</i>	<i>Pfizer; Allergan Aesthetics</i>	<i>Grant - Relationship Ended (Pfizer); Consultant (Allergan Aesthetics)</i>	<i>The relationships are not relevant to the role.</i>
<i>Lisa Curcio, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>David Euhus, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kevin Hughes, MD</i>	<i>Moderator, Program Approver (Board of Directors)</i>	<i>Volpara; Hologic; TME - Targeted Medical Education; Invitae; 23&Me; CRA Health (Formerly Hughes RiskApps)</i>	<i>Honorarium, Speaker - Relationship Ended (Volpara); Honoraria/consulting fees, Speaker/Consultant (Hologic); Honoraria/consulting fees, Speaker/consultant - genetics education and consulting - Relationship Ended (TME - Targeted Medical Education); Honoraria/consulting fees, Speaker/consultant (Invitae); Honoraria/consulting fees, Speaker/consultant (23&Me); Founder - Ownership Interest (CRA Health - Formerly Hughes RiskApps)</i>	<i>As moderator, Dr. Hughes' financial relationships are relevant to the role. His relationship with CRA Health (Ownership interest) meets ACCME exception 2. When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research, they do not make care recommendations). He is discussing only the methodology of the work and not recommending specific testing or platforms for testing. The session faculty were selected by the annual meeting program chair to address broader implications and recommendations. As program approver (board of director member) Dr. Hughes recused himself from discussions and decisions where a conflict</i>

				of interest could occur related to their financial relationship(s).
<i>Jennifer Plichta, MD, MS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Steven Cai, MD</i>	<i>Moderator</i>	<i>Hologic; PreludeDX</i>	<i>Honorarium, Consultant, speaker (Hologic); Honorarium, Consultant (PreludeDX)</i>	<i>All financial relationships are relevant to the role. However, he is functioning as the moderator of the session and has no prepared slides. The session faculty were selected by the annual meeting program chair to address broader implications and recommendations.</i>
<i>David Edmonson, MD</i>	<i>Speaker</i>	<i>Impedimed</i>	<i>Honorarium; Surgical Advisory Board member</i>	<i>The financial relationship is not relevant to the role.</i>
<i>Ted James, MD</i>	<i>Speaker</i>	<i>Perimeter</i>	<i>Honorarium/Options; Advisory Board</i>	<i>The financial relationship is not relevant to the role.</i>
<i>Sharon Lum, MD, MBA, FACS</i>	<i>Moderator</i>	<i>Myriad; Intuitive; Medtronic</i>	<i>Honorarium; consultant - Relationship Ended (Myriad); Accommodations, Meeting participant - Relationship Ended (Intuitive); Food&Beverage; Meeting participant - Relationship Ended (Medtronic)</i>	<i>Financial relationships are not relevant to the role.</i>
<i>Patricia Clark, MD, FACS, FSSO</i>	<i>Moderator</i>	<i>Integro; Endomag</i>	<i>Consulting fee; Advisor (Integro); Honorarium; Speaker (Endomag)</i>	<i>Financial relationships are not relevant to the role.</i>

<i>Jill Dietz, MD, MHCM</i>	<i>Speaker, Planner (Annual Meeting Committee), Program Approver (Board of Directors)</i>	<i>Peace Medical Consulting, LLC; Cyduct Diagnostics</i>	<i>Honorarium, expenses, consulting fees; Part owner of this company - Owner (Peace Medical Consulting, LLC); Options, Chief Medical Officer - Ownership Interest (Cyduct Diagnostics)</i>	<i>As speaker, Dr. Dietz' relationships with Peace Medical Consulting and Cyduct Diagnostic (Owner and Employee) meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.' Peer review of presentation content was also performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material. Her presentation is about establishing a new curriculum structure than a specific medical/clinical topic. As planner and program approver (board of director member), Dr. Dietz recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s). As planner, the relationships with Peace Medical Consulting and Cyduct Diagnostic (Owner and Employee) meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.' For planning, the CME committee also reviewed how topics and speakers were determined and obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i>
<i>Sadia Khan, DO</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Jessica Ryan, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>William Scarlett, DO, MHCM, FACS, FACOS</i>	<i>Speaker</i>	<i>Medtronic</i>	<i>Honorarium; speaker</i>	<i>Financial relationship is not relevant to the role.</i>
<i>Stephanie Valente, DO, FACS</i>	<i>Speaker</i>	<i>Impedimed; Merit Medical; Pacira; Axogen; Hologic</i>	<i>Honorarium, Advisory Board (Impedimed; Honorarium, Speaker - Relationship Ended (Merit Medical); Honorarium, Speaker - Relationship Ended (Pacira); Honorarium, Advisor (AxoGen); Honorarium, Course Speaker (Hologic)</i>	<i>Dr. Valente's financial relationship with Hologic is relevant to her role. Peer review of presentation content was performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material. The other financial relationships are not relevant.</i>
<i>Michael Berry, MD</i>	<i>Speaker</i>	<i>TransMed7; Aptitude Health; Molli Medical</i>	<i>Consultant, Investor - Ownership Interest, Relationship ended (TransMed7); Honorarium, Consultant (Aptitude Health); Honorarium, Consultant (Molli Medical)</i>	<i>Dr. Berry's relationship with TransMed 7 has ended (ownership interest) and meets ACCME exceptions 'a. When the content of the activity is not related to the business lines or products of their employer/company.' The other financial relationships also are not relevant to the role. Peer review of presentation content was also performed by the CME committee. The presentation and Q&A are without bias and no mention of industry, biopsy technology or anything that Trans med 7 does. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</i>
<i>Chandler Cortina, MD, MS, FSSO, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Kandace McGuire, MD</i>	<i>Speaker</i>	<i>Mammotome, Inc</i>	<i>Honorarium; Advisory board, speaker</i>	<i>The financial relationship is not relevant to the role.</i>
<i>Jamie Patterson, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Theresa Schwartz, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kay Yoon-Flannery, DO, MPH, FACS</i>	<i>Moderator</i>	<i>Dilon Technologies</i>	<i>Honorarium; Consultant</i>	<i>The financial relationship is relevant to role. The session faculty were selected by the annual meeting program chair to address broader implications and recommendations.</i>
<i>Jennifer Gass, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Susan Boolbol, MD</i>	<i>Moderator, Planner (Annual Meeting Committee), Program Approver (Board of Directors)</i>	<i>Peace Medical Consultants LLC</i>	<i>Honorarium; Executive role (Owner)</i>	<i>As moderator, Dr. Boolbol's relationship with Peace Medical Consultants, LLC (owner) met exception a. When the content of the activity is not related to the business lines or products of their employer/company. The presentations were reviewed by the CME committee and were free of commercial bias and promotion. The presentation is about general principles of leadership; not related to the ineligible company. As planner, the relationship Peace Medical Consultants, LLC (owner) 'a. When the content of the activity is not related to the business lines or products of their employer/company. For planning, the CME committee also reviewed how topics and speakers were determined and</i>

				<i>obtained evidence that the topics represented a balanced, non-biased, evidence-based approach. As Program Approver (Board of Director) members recused themselves from discussions and decisions where a conflict of interest could occur.</i>
<i>Judy Boughey, MD</i>	<i>Moderator, Planner (Annual Meeting Committee), Program Approver (Board of Directors)</i>	<i>Eli Lilly; SymBioSis; CairnsSurgical; UptoDate; EndoMag</i>	<i>Research funding (institute), Researcher (Eli Lilly); Research funding, Consultant (SymBioSis); Expenses, DSMB (CairnsSurgical); Royalties (UptoDate); Travel, accommodation, honorarium; speaker - Relationship Ended (EndoMag)</i>	<i>As moderator, the financial relationships are not relevant to the role. As planner and program approver (board of director member), Dr. Boughey recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s). For planning, the CME committee also reviewed how topics and speakers were determined and obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i>
<i>Marta Boyer</i>	<i>Staff</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>David Brenin, MD</i>	<i>Program Approver (Board of Directors)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Katherina Calvillo, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Kjirsten Carlson, MD</i>	<i>Regulatory, Program Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Lynn Dengel, MD</i>	<i>Regulatory, Program Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Meghan Flanagan, MD, MPH</i>	<i>Regulatory, Program Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jennifer Gass, MD</i>	<i>Planner (Annual Meeting Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Janie Grumley, MD</i>	<i>Regulatory, Program Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Regina Hampton, MD</i>	<i>Program Approver (Board of Directors)</i>	<i>Cherry Blossom Intimates, Inc.</i>	<i>Stock options; Co-owner, Vice President (Owner)</i>	<i>As a program approver (board of director member), Dr. Hampton recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Ronda Henry-Tillman, MD</i>	<i>Moderator, Program Approver (Board of Directors)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Nathalie Johnson, MD</i>	<i>Speaker, Planner (Annual Meeting Committee), Program Approver (Board of Directors)</i>	<i>Keliomics</i>	<i>Stock options; Advisory Board</i>	<i>As speaker, Dr. Johnson's relationship with Keliomics (ownership interest) meets ACCME exceptions 'a. When the content of the activity is not related to the business lines or products of their employer/company.' Peer review of presentation content was also performed by the CME committee. The presentation did not mention or promote Keliomics or any related principles. The presentation is free of commercial bias and the content of the presentation does not promote commercial material. As planner and program approver (board of director member), Dr. Johnson recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s). As planner, the Keliomics (stock options) relationship meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.' For planning, the CME committee reviewed how topics and speakers were determined and</i>

				<i>obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i>
<i>David Kaufman, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Brigid Killelea, MD, MPH, FACS</i>	<i>Planner (Annual Meeting Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jillian Lloyd, MD</i>	<i>Regulatory, Program Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Christina Lucara</i>	<i>Staff</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Eric Manahan, MD</i>	<i>Moderator, Planner (Annual Meeting Committee), Program Approver (Board of Directors)</i>	<i>Astrazeneca; Aptitude Health; Myriad Genetics; Elucent; Endomag</i>	<i>Honorarium; Speakers bureau (AstraZeneca); Honorarium; Consultant/Speaker (Aptitude Health); Honorarium; Speaker (Myriad Genetics); Honorarium; Speaker/consultant (Elucent); Honorarium; Speaker (Endomag)</i>	<i>As moderator, financial relationship(s) are not relevant to the role. As planner and program approver (board of director member), Dr. Manahan recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s). For planning, the CME committee reviewed how topics and speakers were determined and obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i>

<i>Cindy Matsen, MD, MSCI, FACS</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Sarah McLaughlin, MD</i>	<i>Speaker, Regulatory, Program Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Toan Nguyen, MD</i>	<i>Program Approver (Board of Directors)</i>	<i>Aptitude Health</i>	<i>Honorarium; consultant/advisor</i>	<i>As program approver (board of director member), Dr. Nguyen recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Terry Sarantou, MD</i>	<i>Program Approver (Board of Directors)</i>	<i>TME (relationship ended)</i>	<i>Honorarium</i>	<i>As a board of director member, Dr. Sarantou recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Ranjna Sharma, MD</i>	<i>Regulatory, Program Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Puneet Singh, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Sarah Tevis, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jennifer Tseng, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>Intuitive Surgical</i>	<i>Site PI on mulitcenter clinical trial</i>	<i>As an Ethics committee member, Dr. Singh recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Tekoah White</i>	<i>Staff</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>